Monheim, Germany
Cube Biotech, founded in 2012, is a Germany-based contract research organization specializing in advancing drug discovery for complex targets, particularly membrane proteins. With a unique synthetic copolymer portfolio, Cube Biotech enables more reliable and native membrane protein research compared to traditional detergents.
Offering tailored non-GMP services, the company assists clients in protein preparation, biophysical target characterization, and structure determination via cryo-EM and assay development. Their service models, ranging from FTE-based to milestone-based, provide flexibility and customization akin to building with Lego bricks.
Positioned within the Biotechnology, Health Care, and Pharmaceutical sectors, Cube Biotech seeks enduring collaborations with industrial and academic partners. The company received its last investment through a buyout on 01 November 2021, backed by ArchiMed. A potential investment in Cube Biotech offers exposure to innovative biotech solutions and a partnership-driven approach to drug discovery.
